A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00312754|
Recruitment Status : Terminated (insufficient enrollment)
First Posted : April 11, 2006
Last Update Posted : September 19, 2016
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Drug: Atazanavir||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||70 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase IV, One-arm, Open-label, Multicenter Study Evaluating Effect of Treatment Change to Atazanavir/Ritonavir on Brachial Endothelial Function of HIV Infected Patient Receiving Function in HIV Infected Patient Receiving Potent Antiretroviral Combination Therapy|
|Study Start Date :||June 2005|
|Actual Primary Completion Date :||April 2007|
|Actual Study Completion Date :||April 2007|
- To demonstrate a significant increase in brachial artery FMD after a 24-week ATV/RTV treatment period.
- The change in FMD from ref. value after a 12-wk ATV/RTV treatment period.
- The proportion of pts w/ virologic rebound after a 24-wk ATV/RTV treatment period.
- The proportion of pts w/ metabolic syndrome after a 24-wk ATV/RTV treament period.-
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00312754
|Bobigny, France, 93009|
|Le Kremlin Bicetre, France, 94270|
|Paris Cedex 15, France, 75908|
|Paris Cedex 20, France, 75970|
|Paris, France, 75651|
|Paris, France, 75877|
|Study Director:||Yacia Bennai, MD||00 33 1 58 83 63 84|